View source for Low-density lipoprotein/en

<languages />
{{Short description|One of the five major groups of lipoprotein}}
[[File:Atheroma.jpg|thumb|256x256px|LDL has been associated with the progression of atherosclerosis and blockage of the artery lumen, because it can carry cholesterol into smaller vessels. But LDL is also essential for carrying lipids that keep the human body alive, including in those small vessels.]]

'''Low-density lipoprotein''' ('''LDL''') is one of the five major groups of [[lipoprotein]] that transport all [[fat]] molecules around the body in extracellular water. These groups, from least dense to most dense, are [[chylomicron]]s (aka [[ULDL]] by the overall density naming convention), [[very low-density lipoprotein]] (VLDL), [[intermediate-density lipoprotein]] (IDL), low-density lipoprotein (LDL) and [[high-density lipoprotein]] (HDL). LDL delivers fat molecules to [[Cell (biology)|cells]]. LDL is involved in [[atherosclerosis]], a process in which it is oxidized within the walls of [[Artery|arteries]].

==Overview==
Lipoproteins transfer [[lipid]]s ([[fat]]s) around the body in the [[extracellular fluid]], making fats available to body cells for [[receptor-mediated endocytosis]]. Lipoproteins are complex particles composed of multiple [[protein]]s, typically 80–100 proteins per particle (organized by a single [[apolipoprotein B]] for LDL and the larger particles). A single LDL particle is about 220–275 [[angstroms]] in diameter, typically transporting 3,000 to 6,000 fat molecules per particle, and varying in size according to the number and mix of fat molecules contained within. The lipids carried include all fat molecules with [[cholesterol]], [[phospholipids]], and [[triglycerides]] dominant; amounts of each vary considerably.

The common clinical interpretation of blood lipid levels is that high LDL is associated with increased risk of [[cardiovascular diseases]].

==Biochemistry==

===Structure===
Each native LDL particle enables emulsification, i.e. surrounding the fatty acids being carried, enabling these fats to move around the body within the water outside cells. Each particle contains a single [[apolipoprotein]] B-100 molecule ([[Apolipoprotein B|Apo B-100]], a protein that has 4536 [[amino acid]] residues and a mass of 514 [[Atomic mass unit|kDa]]), along with 80 to 100 additional ancillary proteins. Each LDL has a highly hydrophobic core consisting of [[Polyunsaturated fat|polyunsaturated fatty acid]] known as [[Linoleic acid|linoleate]] and hundreds to thousands (about 1500 commonly cited as an average) of [[ester]]ified and unesterified cholesterol molecules. This core also carries varying numbers of triglycerides and other fats and is surrounded by a shell of phospholipids and unesterified cholesterol, as well as the single copy of Apo B-100. LDL particles are approximately 22&nbsp;nm (0.00000087&nbsp;in.) to 27.5&nbsp;nm in diameter and have a mass of about 3 million daltons. Since LDL particles contain a variable and changing number of fatty acid molecules, there is a distribution of LDL particle mass and size. Determining the structure of LDL has been a tough task because of its heterogeneous structure. However, the structure of LDL at human body temperature in native condition, with a resolution of about 16 [[Angstroms]] using [[cryogenic electron microscopy]], has been described in 2011.

==Physiology==
LDL particles are formed when triglycerides are removed from VLDL by the [[lipoprotein lipase]] enzyme (LPL) and they become smaller and denser (i.e. fewer fat molecules with same protein transport shell), containing a higher proportion of cholesterol esters.

===Transport into the cell===
When a cell requires additional cholesterol (beyond its current internal [[HMG-CoA reductase|HMGCoA]] production pathway), it synthesizes the necessary [[LDL receptor]]s as well as [[PCSK9]], a [[proprotein convertase]] that marks the LDL receptor for degradation. LDL receptors are inserted into the plasma membrane and diffuse freely until they associate with [[clathrin]]-coated pits. When LDL receptors bind LDL particles in the bloodstream, the clathrin-coated pits are endocytosed into the cell.

Vesicles containing LDL receptors bound to LDL are delivered to the [[endosome]]. In the presence of low [[pH]], such as that found in the endosome, LDL receptors undergo a conformation change, releasing LDL. LDL is then shipped to the [[lysosome]], where [[cholesterol ester]]s in the LDL are [[Hydrolysis|hydrolysed]]. LDL receptors are typically returned to the plasma membrane, where they repeat this cycle. If LDL receptors bind to PCSK9, however, transport of LDL receptors is redirected to the lysosome, where they are degraded.

===Role in the innate immune system===
LDL interfere with the [[quorum sensing]] system that upregulates genes required for invasive ''[[Staphylococcus aureus]]'' infection. The mechanism of antagonism entails binding apolipoprotein B to a ''S. aureus'' [[autoinducer]] pheromone, preventing signaling through its receptor. Mice deficient in apolipoprotein B are more susceptible to invasive bacterial infection.

===LDL size patterns===
LDL can be grouped based on its size: large low density LDL particles are described as ''pattern A'', and small high density LDL particles are ''pattern B''. ''Pattern B'' has been associated by some with a higher risk for [[Coronary artery disease|coronary heart disease]]. This is thought to be because the smaller particles are more easily able to penetrate the [[endothelium]] of [[artery|arterial walls]]. ''Pattern I'', for ''intermediate'', indicates that most LDL particles are very close in size to the normal gaps in the endothelium (26&nbsp;nm). According to one study, sizes 19.0–20.5&nbsp;nm were designated as pattern B and LDL sizes 20.6–22&nbsp;nm were designated as pattern A. Other studies have shown no such correlation at all.

Some evidence suggests the correlation between Pattern B and coronary heart disease is stronger than the correspondence between the LDL number measured in the standard lipid profile test. Tests to measure these LDL subtype patterns have been more expensive and not widely available, so the common lipid profile test is used more often.

There has also been noted a correspondence between higher triglyceride levels and higher levels of smaller, denser LDL particles and alternately lower triglyceride levels and higher levels of the larger, less dense ("buoyant") LDL.

With continued research, decreasing cost, greater availability and wider acceptance of other ''lipoprotein subclass analysis'' assay methods, including [[NMR spectroscopy]], research studies have continued to show a stronger correlation between human clinically obvious cardiovascular events and quantitatively measured particle concentrations.

===Oxidized LDL===
Oxidized LDL is a general term for LDL particles with oxidatively modified structural components. As a result, from [[free radical]] attack, both lipid and protein parts of LDL can be oxidized in the vascular wall. Besides the oxidative reactions taking place in vascular wall, oxidized lipids in LDL can also be derived from oxidized dietary lipids.  Oxidized LDL is known to associate with the development of [[atherosclerosis]], and it is therefore widely studied as a potential risk factor of [[cardiovascular diseases]]. Atherogenicity of oxidized LDL has been explained by lack of recognition of oxidation-modified LDL structures by the LDL receptors, preventing the normal metabolism of LDL particles and leading eventually to development of atherosclerotic plaques. Of the lipid material contained in LDL, various lipid oxidation products are known as the ultimate atherogenic species. Acting as a transporter of these injurious molecules is another mechanism by which LDL can increase the risk of atherosclerosis.

==Testing==
[[Blood tests]] commonly report LDL-C: the amount of cholesterol which is estimated to be contained with LDL particles, on average, using a formula, the [[Friedewald equation]]. In clinical context, mathematically calculated estimates of LDL-C are commonly used as an estimate of how much low density lipoproteins are driving progression of atherosclerosis. The problem with this approach is that LDL-C values are commonly discordant with both direct measurements of LDL particles and actual rates of atherosclerosis progression.

Direct LDL measurements are also available and better reveal individual issues but are less often promoted or done due to slightly higher costs and being available from only a couple of laboratories in the [[United States]]. In 2008, the [[American Diabetes Association|ADA]] and [[American College of Cardiology|ACC]] recognized direct LDL particle measurement by NMR as superior for assessing individual risk of cardiovascular events.

===Estimation of LDL particles via cholesterol content===
Chemical measures of lipid concentration have long been the most-used clinical measurement, not because they have the best correlation with individual outcome, but because these lab methods are less expensive and more widely available.

The lipid profile does not measure LDL particles. It only estimates them using the Friedewald equation
by subtracting the amount of cholesterol associated with other particles, such as [[High density lipoprotein|HDL]] and VLDL, assuming a prolonged fasting state, etc.:
:<math>L \approx C - H - kT</math>
:where ''H'' is HDL cholesterol, ''L'' is LDL cholesterol, ''C'' is total cholesterol, ''T'' are triglycerides, and k is 0.20 if the quantities are measured in mg/dL and 0.45 if in mmol/L.

There are limitations to this method, most notably that samples must be obtained after a 12 to 14 h fast and that LDL-C cannot be calculated if plasma triglyceride is >4.52&nbsp;mmol/L (400&nbsp;mg/dL). Even at triglyceride levels 2.5 to 4.5&nbsp;mmol/L, this formula is considered inaccurate.  If both total cholesterol and triglyceride levels are elevated then a modified formula, with quantities in mg/dL, may be used
:<math>L = C - H - 0.16T</math>

This formula provides an approximation with fair accuracy for most people, assuming the blood was drawn after fasting for about 14 hours or longer, but does not reveal the actual LDL particle concentration because the percentage of fat molecules within the LDL particles which are cholesterol varies, as much as 8:1 variation. There  are several formulas published addressing the inaccuracy in LDL-C estimation. The inaccuracy is based on the assumption that VLDL-C (Very low density lipoprotein cholesterol) is always one-fifth of the triglyceride concentration. A new formulae published recently addresses this issue by using an adjustable factor  or by using a regression equation. There are few studies which have compared the LDL-C values derived form this recently published formula and values obtained by direct enzymatic method. Direct enzymatic method are found to be accurate and it has to be the test of choice in clinical situations. In the resource poor settings, the option of using the formula has to be considered.

However, the concentration of LDL particles, and to a lesser extent their size, has a stronger and consistent correlation with individual clinical outcome than the amount of cholesterol within LDL particles, even if the LDL-C estimation is approximately correct. There is increasing evidence and recognition of the value of more targeted and accurate measurements of LDL particles. Specifically, LDL particle number (concentration), and to a lesser extent size, have shown slightly stronger correlations with atherosclerotic progression and cardiovascular events than obtained using chemical measures of the amount of cholesterol carried by the LDL particles. It is possible that the LDL cholesterol concentration can be low, yet LDL particle number high and cardiovascular events rates are high. Correspondingly, it is possible that LDL cholesterol concentration can be relatively high, yet LDL particle number low and cardiovascular events are also low.

====Normal ranges====
In the US, the [[American Heart Association]], [[National Institutes of Health|NIH]], and [[National Cholesterol Education Program|NCEP]] provide a set of guidelines for fasting LDL-Cholesterol levels, estimated or measured, and risk for heart disease. As of about 2005, these guidelines were:

{| class="wikitable"
! Level [[kilogram|mg]]/[[litre|dL]]
! Level [[mole (unit)|mmol]]/L
! Interpretation
|-
| 25 to <50
| <1.3
| Optimal LDL cholesterol, levels in healthy young children before onset of atherosclerotic plaque in heart artery walls
|-
| <70
| <1.8
| Optimal LDL cholesterol, corresponding to lower rates of progression, promoted as a target option for those known to clearly have advanced symptomatic cardiovascular disease
|-
| <100
| <2.6
| Optimal LDL cholesterol, corresponding to lower, but not zero, rates for symptomatic cardiovascular disease events
|-
| 100 to 129
| 2.6 to 3.3
| Near optimal LDL level, corresponding to higher rates for developing symptomatic cardiovascular disease events
|-
| 130 to 159
| 3.3 to 4.1
| Borderline high LDL level, corresponding to even higher rates for developing symptomatic cardiovascular disease events
|-
| 160 to 199
| 4.1 to 4.9
| High LDL level, corresponding to much higher rates for developing symptomatic cardiovascular disease events
|-
| >200
| >4.9
| Very high LDL level, corresponding to highest increased rates of symptomatic cardiovascular disease events
|}

Over time, with more clinical research, these recommended levels keep being reduced because LDL reduction, including to abnormally low levels, was the most effective strategy for reducing cardiovascular death rates in one large [[double blind]], randomized clinical trial of men with [[hypercholesterolemia]]; far more effective than coronary angioplasty/stenting or bypass surgery.

For instance, for people with known atherosclerosis diseases, the 2004 updated American Heart Association, NIH and NCEP recommendations are for LDL levels to be lowered to less than 70&nbsp;mg/dL, unspecified how much lower. This low level of less than 70&nbsp;mg/dL (higher than [[Tim Russert]]'s value shortly prior to his heart attack) was recommended for primary prevention of 'very-high risk patients' and in secondary prevention as a 'reasonable further reduction'. Lack of evidence for such a recommendation is discussed in an article in the [[Annals of Internal Medicine]]. Statin drugs involved in such clinical trials have [[Pleiotropy (drugs)|numerous physiological effects]] beyond simply the reduction of LDL levels.

It has been estimated from the results of multiple human pharmacologic LDL lowering trials that LDL should be lowered to below 30 to reduce cardiovascular event rates to near zero. For reference, from longitudinal population studies following progression of atherosclerosis-related behaviors from early childhood into adulthood, the usual LDL in childhood, before the development of [[fatty streaks]], is about 35&nbsp;mg/dL. However, all the above values refer to chemical measures of lipid/cholesterol concentration within LDL, not measured low-density lipoprotein concentrations, the accurate approach.

A study was conducted measuring the effects of guideline changes on LDL cholesterol reporting and control for diabetes visits in the US from 1995 to 2004. It was found that although LDL cholesterol reporting and control for diabetes and coronary heart disease visits improved continuously between 1995 and 2004, neither the 1998 ADA guidelines nor the 2001 ATP III guidelines increased LDL cholesterol control for diabetes relative to coronary heart disease.

===Direct measurement of LDL particle concentrations===
There are several competing methods for measurement of lipoprotein particle concentrations and size. The evidence is that the NMR methodology (developed, automated & greatly reduced in costs while improving accuracy as pioneered by [[Jim Otvos]] and associates) results in a 22-25% reduction in cardiovascular events within one year, contrary to the longstanding claims by many in the medical industry that the superiority over existing methods was weak, even by statements of some proponents.

Since the later 1990s, because of the development of NMR measurements, it has been possible to clinically measure lipoprotein particles at lower cost [under $80 US (including shipping) & is decreasing; versus the previous costs of >$400 to >$5,000] and higher accuracy. There are two other assays for LDL particles, however, like LDL-C, most only estimate LDL particle concentrations.

Direct LDL particle measurement by NMR was mentioned by the ADA and ACC, in a 28 March 2008 joint consensus statement, as having advantages for predicting individual risk of atherosclerosis disease events, but the statement noted that the test is less widely available, is more expensive [about $13.00 US (2015 without insurance coverage) from some labs which use the Vantera Analyzer]. Debate continues that it is "...unclear whether LDL particle size measurements add value to measurement of LDL-particle concentration", though outcomes have always tracked LDL particle, not LDL-C, concentrations.

Using NMR, the total LDL particle concentrations, in nmol/L plasma, are typically subdivided by percentiles referenced to the 5,382 men and women, not on any lipid medications, who are participating in the MESA trial.

====Optimal ranges====
The LDL particle concentrations are typically categorized by percentiles, <20%, 20–50%, 50th–80th%, 80th–95% and >95% groups of the people participating and being tracked in the MESA trial, a medical research study sponsored by the United States National Heart, Lung, and Blood Institute.

{| class="wikitable"
! MESA Percentile
! LDL particles nmol/L
! Interpretation
|-
| 0–20%
| <1,000
| Those with lowest rate of cardiovascular disease events & low (optimal) LDL particle concentration
|-
| 20–50%
| 1,000–1,299
| Those with moderate rate of cardiovascular disease events & moderate LDL particle concentration
|-
| 50–80%
| 1,300–1,599
| Those with Borderline-High rate of cardiovascular disease events & higher LDL particle concentration
|-
| 89–95%
| 1,600–2,000
| Those with High rate of cardiovascular disease events and even higher LDL particle concentration
|-
| >95%
| >2,000
| Those with very high rate of cardiovascular disease events and highest LDL particle concentration
|-
|}

The lowest incidence of atherosclerotic events over time occurs within the <20% group, with increased rates for the higher groups. Multiple other measures, including particle sizes, small LDL particle concentrations, large total and HDL particle concentrations, along with estimations of [[insulin resistance]] pattern and standard cholesterol lipid measurements (for comparison of the plasma data with the estimation methods discussed above) are also routinely provided.

==Lowering LDL-cholesterol==
{| class="wikitable" style="float:right; width:40em; border:solid 1px #999999; margin:0 0 1em 1em;"
|-
! colspan=5 style="background-color: #CCEEEE;" | Markers indicating a need for LDL-C Reduction
(Per 2004 United States Government Minimum Guidelines)
|-
! If the patient's cardiac risk is...
! then the patient should consider LDL-C reduction if the count in mg/dL is over...
! and LDL-C reduction is indicated if the count in mg/dL is over...
|-
| High, meaning a 20% or greater risk of heart attack within 10 years, or an extreme risk factor
| 70
| 100
|-
| moderately high, meaning a 10-20% risk of heart attack within 10 years and more than 2 heart attack risk factors
| 100
| 130
|-
| moderate, meaning a 10% risk of heart attack within 10 years and more than 2 heart attack risk factors
| 130
| 160
|-
| low, meaning less than 10% risk of heart attack within 10 years and 1 or 0 heart attack risk factors
| 160
| 190
|-
|}

The [[mevalonate pathway]] serves as the basis for the biosynthesis of many molecules, including cholesterol. The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase ([[HMG CoA reductase]]) is an essential component and performs the first of 37 steps within the cholesterol production pathway, and is present in every animal cell.

LDL-C is not a measurement of actual LDL particles. LDL-C is only an estimate (not measured from the individual's blood sample) of how much cholesterol is being transported by all LDL particles, which is either a smaller concentration of large particles or a high concentration of small particles. LDL particles carry many fat molecules (typically 3,000 to 6,000 fat molecules per LDL particle); this includes cholesterol, triglycerides, phospholipids and others. Thus even if the hundreds to thousands of cholesterol molecules within an average LDL particle were measured, this does not reflect the other fat molecules or even the number of LDL particles.

=== Pharmaceutical ===
* [[PCSK9 inhibitor]]s, in clinical trials, by several companies, are more effective for LDL reduction than the statins, including statins alone at high dose (though not necessarily the combination of statins plus ezetimibe).
* [[Statin]]s reduce high levels of LDL particles by inhibiting the enzyme HMG-CoA reductase in cells, the rate-limiting step of cholesterol synthesis. To compensate for the decreased cholesterol availability, synthesis of LDL receptors (including hepatic) is increased, resulting in an increased clearance of LDL particles from the extracellular water, including of the blood.
* [[Ezetimibe]] reduces intestinal absorption of cholesterol, thus can reduce LDL particle concentrations when combined with statins.
* [[Niacin (substance)|Niacin]] (B<sub>3</sub>), lowers LDL by selectively inhibiting hepatic diacylglycerol acyltransferase 2, reducing [[triglyceride]] synthesis and VLDL secretion through a receptor HM74 and HM74A or GPR109A.
* Several [[CETP inhibitor]]s have been researched to improve HDL concentrations, but so far, despite dramatically increasing HDL-C, have not had a consistent track record in reducing atherosclerosis disease events. Some have increased mortality rates compared with placebo.
* [[Clofibrate]] is effective at lowering cholesterol levels, but has been associated with significantly increased cancer and stroke mortality, despite lowered cholesterol levels. Other, more recently developed and tested fibrates, e.g. fenofibric acid have had a better track record and are primarily promoted for lowering VLDL particles (triglycerides), not LDL particles, yet can help some in combination with other strategies.
* Some [[tocotrienol]]s, especially delta- and gamma-tocotrienols, are being promoted as statin alternative non-prescription agents to treat high cholesterol, having been shown in vitro to have an effect. In particular, gamma-tocotrienol appears to be another HMG-CoA reductase inhibitor, and can reduce cholesterol production. As with statins, this decrease in intra-hepatic (liver) LDL levels may induce hepatic LDL receptor up-regulation, also decreasing plasma LDL levels. As always, a key issue is how benefits and complications of such agents compare with statins—molecular tools that have been analyzed in large numbers of human research and clinical trials since the mid-1970s.
* [[Phytosterol]]s are widely recognized as having a proven LDL cholesterol lowering efficacy' A 2018 review found a dose-response relationship for phytosterols, with intakes of 1.5 to 3&nbsp;g/day lowering LDL-C by 7.5% to 12%, but reviews as of 2017 had found  no data indicating that the consumption of phytosterols may reduce the risk of CVD. Current supplemental guidelines for reducing LDL recommend doses of phytosterols in the 1.6-3.0&nbsp;grams per day range (Health Canada, EFSA, ATP III, FDA) with a 2009 meta-analysis demonstrating an 8.8% reduction in LDL-cholesterol at a mean dose of 2.15&nbsp;gram per day.

=== Gene editing ===
In 2021, scientists demonstrated that [[CRISPR gene editing]] can decrease blood levels of LDL cholesterol in vivo in ''[[Macaca fascicularis]]'' monkeys for months by 60% via knockout of [[PCSK9]] in the liver.

=== Lifestyle ===
LDL cholesterol can be lowered by through dietary intervention by limiting foods with [[saturated fat]] and avoiding foods with [[trans fat]]. Saturated fats are found in meat products (including poultry), full-fat dairy, eggs, and refined tropical oils like coconut and palm. However, trans fat can still be found in red meat and dairy products as it is produced in small amounts by ruminants such as sheep and cows. LDL cholesterol can also be lowered by increasing consumption of soluble fiber and plant-based foods.

Another lifestyle approach to reduce LDL cholesterol has been minimizing total body fat, in particular fat stored inside the [[abdominal cavity]] ([[Adipose tissue|visceral body fat]]). Visceral fat, which is more metabolically active than subcutaneous fat, has been found to produce many enzymatic signals, e.g. [[resistin]], which increase [[insulin resistance]] and circulating VLDL particle concentrations, thus both increasing LDL particle concentrations and accelerating the development of diabetes mellitus.

==See also==
{{Columns-list|colwidth=30em|
* [[Catechin]]
* [[Cholesterol]]
* [[Lysosomal acid lipase deficiency]]
* [[Cholesteryl ester storage disease]]
* [[Coenzyme Q10]]
* [[Flavonoid]]
* [[Glutathione]]
* [[Health effects of tea]]
* [[High density lipoprotein]]
* [[LDL receptor]]
* [[Lipid profile]]
* [[Lipoprotein(a)]]
* [[Lipoprotein-X]]
* [[Melatonin]]
* [[Polyphenol antioxidant]]
* [[Saturated fat]]
* [[Stanol ester]]
* [[Sterol ester]]
* [[Triglyceride]]
* [[Vitamin A]]
* [[Vitamin C]]
* [[Vitamin E]]
}}

==External links==
* [https://www.youtube.com/watch?v=XPguYN7dcbE Fat (LDL) Degradation]: PMAP [[The Proteolysis Map]]-animation
* [https://web.archive.org/web/20050524010904/http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm Adult Treatment Panel III Full Report]
* [https://web.archive.org/web/20140202053506/http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm ATP III Update 2004]
* {{Cite journal|vauthors=O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R |title=Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal |journal=Journal of the American College of Cardiology |volume=43 |issue=11 |pages=2142–6 |date=June 2004 |pmid=15172426 |doi=10.1016/j.jacc.2004.03.046|doi-access= }}

{{Lipoproteins}}
{{Vascular diseases}}
{{Portal bar|Biology}}

{{二次利用|date=16 February 2024}}
{{DEFAULTSORT:Low-Density Lipoprotein}}
[[Category:Cardiology]]
[[Category:Lipid disorders]]
[[Category:Lipoproteins]]